Incretin therapy and its effect on body weight in patients with diabetes

• Glucagon-like peptide 1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors are two classes of treatments for type 2 diabetes, which enhance the well-known 'incretin effect' of increased insulin secretion in response to food intake. This concise review introduces both types of incretin-based therapies and focuses on the extra-pancreatic effect of GLP-1 on body weight. As well as improving glycaemic control in subjects with type 2 diabetes, these treatments have the additional benefits of improving weight management in these patients, with GLP-1 receptor agonists causing weight loss and DPP-4 inhibitors being weight neutral. (C) 2012 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Nyckelord

Glucagon-like peptide 1 (GLP-1)

receptor agonist

Dipeptidyl peptidase-4 (DPP-4) inhibitor

Body

glucagon-like peptide-1

dipeptidyl peptidase-4 inhibitors

life-style

modification

receptor agonists

open-label

exenatide

mellitus

glucose

tolerability

strategies

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)